Tamsulosin vs Tolterodine in the Management of Ureteric Stent Related Symptoms Following Ureterorenoscopy

Abstract

Background: Indwelling ureteric stents produce varying degrees of complication and discomforts ranging from frequency and urgency to haematuria or infection and signicantly impacts quality of life. Aim: assess the effectiveness of Tamsulosin and tolterodine in improving the lower urinary tract symptoms of patients with indwelling double –J- ureteric stents following ureterorenoscopy Methods: The study was conducted in randomized, double-blind manner in department of general surgery , NMCH ,Patna from 1st January 2014 to 10th June 2015. In total, 40 patients with double J stent were randomly divided into two groups (group A, n: 20, group B, n: 20 ). Each patient randomly received one pack of drug in different colours of the content to take Tamsulosin 0.4 mg before sleep, Tolterodine 4 mg once a day : group A received Tolterodine , group 2 Tamsulosin a for 1 month in a double-blind manner. Ureteral stent-related morbidity indices which analysed included urinary symptom, pain, general health, quality of work and sex scores were measured by Ureteral Symptom Score Questionnaire for rst and fourth weeks after drug consumption and the rst week after double J stent removal. Results: No signicant change in various domains of USSQ like urinary symptoms , body pain, general health , work performance , sexual matters. Conclusions: Both drugs minimise the symptoms however a larger well-designed study needs to be conducted to conrm the ndings.

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis

“…We followed the above search strategy and eventually retrieved 239 articles, 206 of which were excluded by eliminating duplicates and filtering titles and abstracts. Of the remaining 33 articles, 25 were excluded due to either not being found in the literature search or lacking valid data after reading the full articles, and eight studies were ultimately included to evaluate the efficacy and safety of tolterodine and α-adrenergic receptor blockers for the treatment of ureteral stent-related symptoms [8,[13][14][15][16][17][18][19]. The details, characteristics, and baseline summaries of the included studies are shown in Table 1.…”